GCM
CELU icon

Gladius Capital Management’s Celularity CELU Stock Holding History

Gladius Capital Management’s Portfolio CELU Stock Details CELU Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q2 		– Sell
-4,184
Closed -$25.9K – 380
2023
Q1 		$25.9K Buy
+4,184
New +$33.7K ﹤0.01% 305

Other funds holding CELU

SIC
Starr International Company Zug, Switzerland $19.9M AUM 39.69% 1-Year Est. Return
CVSC
C.V. Starr & Co New York $192M AUM 35.69% 1-Year Est. Return
AC
Armistice Capital New York $5.62B AUM 36.06% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
BFO
Biltmore Family Office Charlotte, North Carolina $716M AUM 21.09% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
Royal Bank of Canada
Royal Bank of Canada Toronto, Ontario, Canada $570B AUM 27.57% 1-Year Est. Return

Gladius Capital Management's CELU Position: Q2 2023 in Review

Gladius Capital Management sold out of Celularity (CELU) in Q2 2023, closing a stake of 4,184 shares — an estimated $25.9K sold.

Gladius Capital Management first reported a position in CELU in Q1 2023 and held it in 1 quarter. The position peaked at $25.9K in Q1 2023. 56 funds tracked by Wall St. Rank hold CELU as of Q2 2023.

  • Gladius Capital Management reported no remaining Celularity position as of Q2 2023 after selling out during the quarter.
  • Gladius Capital Management sold 4,184 Celularity shares in Q2 2023, an estimated $25.9K.
  • Gladius Capital Management first reported a position in Celularity in Q1 2023 and held it in 1 quarter.
  • Gladius Capital Management's Celularity position peaked at $25.9K in Q1 2023.
  • 56 funds tracked by Wall St. Rank held Celularity as of Q2 2023.

Based on Gladius Capital Management's 13F filing for Q2 2023, filed 8 Aug 2023.